BR112017013398A2 - método de fabricar proteína - Google Patents

método de fabricar proteína

Info

Publication number
BR112017013398A2
BR112017013398A2 BR112017013398A BR112017013398A BR112017013398A2 BR 112017013398 A2 BR112017013398 A2 BR 112017013398A2 BR 112017013398 A BR112017013398 A BR 112017013398A BR 112017013398 A BR112017013398 A BR 112017013398A BR 112017013398 A2 BR112017013398 A2 BR 112017013398A2
Authority
BR
Brazil
Prior art keywords
protein
making method
protein making
provides
linked
Prior art date
Application number
BR112017013398A
Other languages
English (en)
Other versions
BR112017013398B1 (pt
Inventor
Mark ILLIDGE Christopher
Alan Watson Neil
Original Assignee
Ucb Biopharma Sprl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ucb Biopharma Sprl filed Critical Ucb Biopharma Sprl
Publication of BR112017013398A2 publication Critical patent/BR112017013398A2/pt
Publication of BR112017013398B1 publication Critical patent/BR112017013398B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/113—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure
    • C07K1/1133—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure by redox-reactions involving cystein/cystin side chains
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J47/00—Ion-exchange processes in general; Apparatus therefor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/18—Ion-exchange chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/36—Extraction; Separation; Purification by a combination of two or more processes of different types
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0018—Culture media for cell or tissue culture
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/50—Soluble polymers, e.g. polyethyleneglycol [PEG]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines

Abstract

a presente invenção fornece um novo método para fabricar uma proteína, particularmente onde a dita proteína deva ser ligada com uma outra molécula. a invenção fornece ainda um método para a fabricação de proteína em escala industrial para se obter proteínas, por exemplo, para propósitos terapêuticos.
BR112017013398-9A 2014-12-22 2015-12-18 Método de fabricar anticorpo ou fragmento de ligação ao antígeno do mesmo BR112017013398B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14199722 2014-12-22
EP14199722.1 2014-12-22
PCT/EP2015/080526 WO2016102378A1 (en) 2014-12-22 2015-12-18 Method of protein manufacture

Publications (2)

Publication Number Publication Date
BR112017013398A2 true BR112017013398A2 (pt) 2018-03-06
BR112017013398B1 BR112017013398B1 (pt) 2023-12-05

Family

ID=52282495

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017013398-9A BR112017013398B1 (pt) 2014-12-22 2015-12-18 Método de fabricar anticorpo ou fragmento de ligação ao antígeno do mesmo

Country Status (16)

Country Link
US (1) US10626143B2 (pt)
EP (1) EP3237433A1 (pt)
JP (1) JP6807326B2 (pt)
KR (1) KR102537099B1 (pt)
CN (1) CN107108691B (pt)
AU (1) AU2015371341B2 (pt)
BR (1) BR112017013398B1 (pt)
CA (1) CA2969981A1 (pt)
CL (1) CL2017001633A1 (pt)
CO (1) CO2017006157A2 (pt)
EA (1) EA039002B1 (pt)
IL (1) IL252712B2 (pt)
MX (1) MX2017007670A (pt)
MY (1) MY184085A (pt)
SG (1) SG11201704841UA (pt)
WO (1) WO2016102378A1 (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2969889A1 (en) 2014-12-22 2016-06-30 Ucb Biopharma Sprl Protein manufacture
CN110386978A (zh) * 2018-04-19 2019-10-29 上海多米瑞生物技术有限公司 大肠杆菌周质空间表达的蛋白的提取方法
CN111965356B (zh) * 2019-11-28 2023-09-08 上海荣盛生物药业股份有限公司 巯基还原组合物及荧光微球层析试纸和应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9215540D0 (en) 1992-07-22 1992-09-02 Celltech Ltd Protein expression system
US5655866A (en) 1995-03-20 1997-08-12 Bellanca; Joseph V. Method of folding a signature for use in bookbinding
EP1161440A1 (en) * 1999-03-17 2001-12-12 Medical Research Council Method for refolding molecules of polypeptides containing ig domains
GB0013810D0 (en) 2000-06-06 2000-07-26 Celltech Chiroscience Ltd Biological products
JP5553963B2 (ja) * 2004-10-22 2014-07-23 アムジエン・インコーポレーテツド 組換え抗体をリフォールディングする方法
EP1805205A1 (en) * 2004-10-22 2007-07-11 Amgen Inc. Methods for refolding polypeptides
GB0425534D0 (en) 2004-11-19 2004-12-22 Celltech R&D Ltd Process for obtaining antibodies
GB0513852D0 (en) * 2005-07-06 2005-08-10 Celltech R&D Ltd Biological products
CN101506222B (zh) 2006-07-14 2013-10-02 健泰科生物技术公司 重组蛋白的重折叠
WO2008076933A2 (en) * 2006-12-14 2008-06-26 Bolder Biotechnology, Inc. Long acting proteins and peptides and methods of making and using the same
GB201001791D0 (en) 2010-02-03 2010-03-24 Ucb Pharma Sa Process for obtaining antibodies
CN102892780B (zh) 2010-03-17 2015-07-29 通益制药有限公司 获得生物活性的重组人g-csf的方法
GB201012603D0 (en) 2010-07-27 2010-09-08 Ucb Pharma Sa Protein purification
GB201012599D0 (en) 2010-07-27 2010-09-08 Ucb Pharma Sa Process for purifying proteins
KR20130140010A (ko) 2010-10-20 2013-12-23 메디뮨 엘엘씨 봉입체의 가공처리 방법
CA2969889A1 (en) 2014-12-22 2016-06-30 Ucb Biopharma Sprl Protein manufacture
GB201506870D0 (en) 2015-04-22 2015-06-03 Ucb Biopharma Sprl Method

Also Published As

Publication number Publication date
KR102537099B1 (ko) 2023-05-25
JP2018505210A (ja) 2018-02-22
CA2969981A1 (en) 2016-06-30
US20170342105A1 (en) 2017-11-30
IL252712A0 (en) 2017-08-31
EP3237433A1 (en) 2017-11-01
CN107108691A (zh) 2017-08-29
MY184085A (en) 2021-03-17
CL2017001633A1 (es) 2017-11-24
CO2017006157A2 (es) 2017-09-20
IL252712B2 (en) 2024-04-01
AU2015371341B2 (en) 2021-05-20
BR112017013398B1 (pt) 2023-12-05
EA039002B1 (ru) 2021-11-19
AU2015371341A1 (en) 2017-06-29
US10626143B2 (en) 2020-04-21
CN107108691B (zh) 2021-06-29
EA201791423A1 (ru) 2017-10-31
WO2016102378A1 (en) 2016-06-30
MX2017007670A (es) 2017-10-27
JP6807326B2 (ja) 2021-01-06
KR20170090510A (ko) 2017-08-07
SG11201704841UA (en) 2017-07-28
IL252712B1 (en) 2023-12-01

Similar Documents

Publication Publication Date Title
DK4023755T3 (da) Kunstige nukleinsyremolekyler til forbedret proteinudtrykkelse
BR112019000718A2 (pt) processo para a produção de geopolímero ou compósito de geopolímero
BR112017023374A2 (pt) formulação de anticorpo anti-cgrp
TWD170641S (zh) 生物感測器腕帶
BR112016028045A8 (pt) biopolímeros modificados, e seus métodos de produção
BR112017013956B8 (pt) Proteínas de fusão de citocinas
BR112017013394A2 (pt) fabricação de proteína
UY37035A (es) MOLÉCULAS DE ANTICUERPO MULTIESPECÍFICO CON ESPECIFICIDAD POR TNF-ALFA, IL-17A e IL-17F
DK3419991T3 (da) Modificerede ribosomale genpromotorer til proteinproduktion i mikroorganismer
BR112016024895A2 (pt) fator secretório de proteína com alta eficácia secretória e um vetor de expressão compreendendo o mesmo
BR112017005109A2 (pt) produto refratário com base em al2o3, composição de matérias-primas para a fabricação do produto, método para a fabricação de um produto refratário, produto refratário, e emprego do produto refratário
BR112016015218A2 (pt) microrganismo com capacidade melhorada de produção de l-treonina e método para produzir l-treonina com o uso desse
BR112016007166A2 (pt) derivado de um análogo de insulina
BR112016025898A2 (pt) ?drimenol sintases e método para produzir drimenol?
BR112016019389A2 (pt) vacina, e, peptídeo
CR20150544A (es) Proteinas específicas para el baff y para la b7rp1 y sus usos
BR112017001391A2 (pt) componentes para o fusionamento de corpos vertebrais
BR112018012851A2 (pt) cepas de expressão de proteína melhoradas
BR112016019390A2 (pt) proteínas de fusão uti
BR112017013398A2 (pt) método de fabricar proteína
BR112017018993A2 (pt) Processo para preparar 3-cloro-2- vinilfenilassulfonatos
BR112018012193A2 (pt) variantes do polipeptídeo de fusão relacionados à ômega-hidroxilase com propriedades melhoradas
BR112017025873A2 (pt) método para revestir a cabeça de um pirulito com um material de revestimento
BR112019006956A2 (pt) ketchup de tomate com estabilidade de armazenamento aperfeiçoada
BR112016025905A2 (pt) drimenol sintases ii

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 18/12/2015, OBSERVADAS AS CONDICOES LEGAIS